Trial Search Results

68Ga-PSMA PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

This phase II/III trial studies gallium 68 Ga (68Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography/magnetic resonance imaging (PET/MRI) in finding tumors in patients with prostate cancer undergoing surgery that tend to spread quickly (intermediate-risk) or is likely to come back or spread (high-risk). Diagnostic procedures, such as PET/MRI, may help find and diagnose prostate cancer and find out how far the disease has spread. Radioactive drugs, such as gallium Ga 68-PSMA, binds to tumor cells that have specific receptors, and may allow doctors to see smaller tumors than the standard of care contrast-enhanced computed tomography (CT) or MRI scan.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Andrei Iagaru

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Drug: gallium Ga 68-PSMA
  • Procedure: Magnetic Resonance Imaging
  • Procedure: Positron Emission Tomography


Phase 2/Phase 3


Inclusion Criteria:

   - Biopsy proven prostate adenocarcinoma

   - Planned prostatectomy with lymph node dissection

   - Intermediate to high-risk disease (as determined by elevated prostate-specific antigen
   [PSA] [PSA > 10], T-stage [T2b or greater], Gleason score [Gleason score > 6] or other
   risk factors)

   - No evidence of metastatic disease on conventional imaging, including a negative bone
   scan for skeletal metastasis and/or negative cross section imaging (MR or CT)

   - Able to provide written consent

   - Karnofsky performance status of >= 50 (Eastern Cooperative Oncology Group [ECOG]/World
   Health Organization [WHO] equivalent)

   - No history of renal insufficiency

Exclusion Criteria:

   - Patients not capable of getting PET study due to weight, claustrophobia, or inability
   to lay still for the duration of the exam

   - Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy

   - Androgen deprivation therapy prior to PET imaging

   - Metallic implants

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Risa Jiron